Targeting CHEK2-YBX1/3 axis to enhance response to immune checkpoint blockade therapy in gliomas
收藏NIAID Data Ecosystem2026-05-02 收录
官方服务：
资源简介：
Target CHEK2 to inhance immune checkpoint blockade in glioma
应用场景：
创建时间：
2025-03-07
相关数据集
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin)
drugs targeting mitosis might affect the tumor microenvironment and sensitize cancer cells to immunotherapy. BAL101553 monotherapy increased survival in immune checkpoint blockadeâresistant SB28 gli
NIAID Data Ecosystem40
Table_1_Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma.xlsx
BackgroundPyroptosis is a critical type of programmed cell death that is strongly associated with the regulation of tumor and immune cell functions. However, the role of pyroptosis in tumor progressio
NIAID Data Ecosystem30
Epigenetic priming induces cancer testis antigens and human endogenous retroviruses in glioma for enhanced T cell responses at single cell resolution (methylation). Epigenetic priming induces cancer testis antigens and human endogenous retroviruses in glioma for enhanced T cell responses at single cell resolution (methylation)
Glioblastoma (GBM) is the most common malignant primary brain tumor and remains incurable. Previous work has shown that systemic administration of Decitabine (DAC) induces sufficient expression of NY-
NIAID Data Ecosystem10
Table_1_An Immune Gene-Related Five-lncRNA Signature for to Predict Glioma Prognosis.DOCX
BackgroundThe tumor immune microenvironment is closely related to the malignant progression and treatment resistance of glioma. Long non-coding RNA (lncRNA) plays a regulatory role in this process. We
NIAID Data Ecosystem30
DataSheet1_Unveiling the landscape of cytokine research in glioma immunotherapy: a scientometrics analysis.xlsx
Background: Cytokines modulate the glioma tumor microenvironment, influencing occurrence, progression, and treatment response. Strategic cytokine application may improve glioma immunotherapy outcomes.
NIAID Data Ecosystem10
